These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7995015)

  • 41. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal.
    Fowler JS; Volkow ND; Logan J; Wang GJ; MacGregor RR; Schyler D; Wolf AP; Pappas N; Alexoff D; Shea C
    Synapse; 1994 Oct; 18(2):86-93. PubMed ID: 7839316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels.
    Steyn SJ; Castagnoli K; Steyn S; Castagnoli N
    Exp Neurol; 2001 Apr; 168(2):434-6. PubMed ID: 11259132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M; Willoughby J; Glover V; Gibb C
    J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
    Naoi M; Maruyama W; Inaba-Hasegawa K
    Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.
    Freedman NM; Mishani E; Krausz Y; Weininger J; Lester H; Blaugrund E; Ehrlich D; Chisin R
    J Nucl Med; 2005 Oct; 46(10):1618-24. PubMed ID: 16204711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monoamine oxidase, dopamine and Parkinson's disease.
    Oreland L
    Acta Neurol Scand Suppl; 1991; 136():60-5. PubMed ID: 1801538
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
    Fuller RW; Robertson DW; Hemrick-Luecke SK
    J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition.
    Le W; Jankovic J; Xie W; Kong R; Appel SH
    Neurosci Lett; 1997 Mar; 224(3):197-200. PubMed ID: 9131670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological and clinical implications of MAO-B inhibitors.
    Yu PH
    Gen Pharmacol; 1994 Dec; 25(8):1527-39. PubMed ID: 7721026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. L-deprenyl (selegiline) decreases excitatory synaptic transmission in the rat hippocampus via a dopaminergic mechanism.
    Hsu KS; Huang CC; Su MT; Tsai JJ
    J Pharmacol Exp Ther; 1996 Nov; 279(2):740-7. PubMed ID: 8930179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
    Finnegan KT; Irwin I; Delanney LE; Langston JW
    J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, lipoic acid and L-deprenyl on the interplay between cellular redox systems.
    Götz ME; Dirr A; Gsell W; Burger R; Janetzky B; Freyberger A; Reichmann H; Rausch WD; Riederer P
    J Neural Transm Suppl; 1994; 43():145-62. PubMed ID: 7884397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selegiline--an overview of its role in the treatment of Parkinson's disease.
    Wessel K; Szelenyi I
    Clin Investig; 1992 May; 70(5):459-62. PubMed ID: 1600360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. R-deprenyl: pharmacological spectrum of its activity.
    Magyar K; Szende B; Jenei V; Tábi T; Pálfi M; Szöko E
    Neurochem Res; 2010 Dec; 35(12):1922-32. PubMed ID: 20725780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
    Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
    Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What is it that l-deprenyl (selegiline) might do?
    Tipton KF
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):781-96. PubMed ID: 7995021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.